Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson's: a systematic review by Xin, Yiqiao & McIntosh, Emma
 
 
 
 
Xin, Y. and McIntosh, E. (2017) Assessment of the construct validity and 
responsiveness of preference-based quality of life measures in people with 
Parkinson's: a systematic review. Quality of Life Research, 26(1), pp. 1-23. 
(doi:10.1007/s11136-016-1428-x) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/130561/ 
     
 
 
 
 
 
 
Deposited on: 15 November 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
1 
 
Title:  
Assessment of the construct validity and responsiveness of preference-based quality of life measures 
in people with Parkinson’s: a systematic review 
Authors:  
Yiqiao Xin, Emma McIntosh 
Concise and informative title: 
Measuring preference-based quality of life in Parkinson’s 
Affiliation and address:  
Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing 
(IHW), University of Glasgow. 1 Lilybank Gardens, Glasgow G12 8RZ. 
Corresponding author: 
Yiqiao Xin 
Yiqiao.xin@glasgow.ac.uk 
Tel: +44 (0) 141 330 6245 
Fax: +44 (0) 141 330 5018 
 
2 
 
 
Abstract: 
Purpose 
Generic preference-based quality of life (PbQoL) measures are sometimes criticised for being 
insensitive or failing to capture important aspects of quality of life (QoL) in specific populations. The 
objective of this study was to systematically review and assess the construct validity and 
responsiveness of PbQoL measures in Parkinson’s. 
Methods 
Ten databases were systematically searched up to July 2015. Studies were included if a PbQoL 
instrument along with a common Parkinson’s clinical or QoL measure was used, and the utility values 
were reported. The PbQoL instruments were assessed for construct validity (discriminant and 
convergent validity) and responsiveness. 
Results 
Twenty-three of 2,758 studies were included, of which the majority evidence was for EQ-5D. Overall, 
good evidence of discriminant validity was demonstrated in the Health Utility Index (HUI)-3, EQ-5D-5L, 
EQ-5D-3L, 15D, HUI-2 and Disability and Distress Index (DDI). Nevertheless, HUI-2 and EQ-5D-3L 
were shown to be less sensitive among patients with mild Parkinson’s. Moderate to strong correlations 
were shown between the PbQoL measures (EQ-5D-3L, EQ-5D-5L, 15D, DDI, and HUI-II) and 
Parkinson’s-specific measures. Twelve studies provided evidence for the assessment of 
responsiveness of EQ-5D-3L and one study for 15D, among which six studies reached inconsistent 
results between EQ-5D-3L and the Parkinson’s-specific measures in measuring the change overtime. 
Conclusions 
The construct validity of the PbQoL measures was generally good, but there are concerns regarding 
their responsiveness to change. In Parkinson’s, the inclusion of a Parkinson’s-specific QoL measure or 
a generic but broader scoped mental and well-being focused measure to incorporate aspects not 
included in the common PbQoL measures is recommended. 
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Abbreviations 
AQoL Assessment of Quality of Life 
CBA Cost-benefit analysis 
CS-PBM Condition-specific preference-based measure 
CUA Cost-utility analysis 
DDI Disability and Distress Index 
EQ-5D EuroQoL EQ-5D 
HAD Hospital Anxiety and Depression scale 
HUI Health Utilities Index 
H&Y Hoehn and Yahr scale 
ICER Incremental cost-effectiveness ratio 
MCID Minimal clinically important difference 
NICE National Institute for Health and Care Excellence 
PbQoL Preference-based quality of life 
PDQ-39 Parkinson’s Disease Questionnaire-39-item 
PDQ-39-SI Parkinson’s disease questionnaire-39-item-Summary Index 
PDQL Parkinson’s Disease Quality of Life questionnaire 
PDQUALIF Parkinson’s disease QUAlity LIFe scale 
PwP People with Parkinson’s 
QALY Quality-adjusted life-years 
QoL Quality of life 
RCT Randomised controlled trials 
SF-6D Short-Form 6-Dimension 
SF-36 Short-Form 36-item 
SG Standard gamble 
TTO Time trade-off 
UPDRS Unified Parkinson’s Disease Rating Scale 
VAS Visual analogue scale 
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Introduction 
Health state utilities or preference-based quality of life (PbQoL) values are an important parameter in 
economic evaluations due to their role in the calculation of quality-adjusted life-years (QALYs) for 
economic evaluations. Typically, incremental QALYs are combined with incremental costs to calculate 
the incremental cost-effectiveness ratio (ICER) in cost-utility analysis (CUA) [1]. CUA is the preferred 
form of economic evaluation of  government advisory bodies such as the UK’s National Institute for 
Health and Care Excellence (NICE) for priority setting across disease areas [2].  
To generate QALY’s, PbQoL measures are needed. PbQoL measures often comprise a descriptive 
system (i.e., attributes (or dimensions) and levels) and a value set. The value set typically reflects the 
preferences of a representative population sample for each of the health states defined by the profile 
of attributes and levels. These values are commonly elicited using methods such as the standard 
gamble (SG) [3,4] and time trade-off (TTO) [5]. PbQoL measures typically contain generic attributes, 
thus facilitating comparative analysis across health areas to assist priority setting. Widely used 
examples of generic measures include the EuroQoL EQ-5D (EQ-5D 3L and 5L versions) [6,7], Short-
Form 6-Dimension (SF-6D) [8], and Health Utilities Index (HUI) [9,10]. The EQ-5D is recommended by 
UK’s NICE to be used in the reference case of economic evaluations [11]. 
However, the validity of applying such generic measures in some specific populations is the subject of 
some debate. Generic measures have sometimes been found to be less sensitive to detect changes in 
quality of life (QoL) in specific populations, for example mental health [12], schizophrenia [13], cancer 
[14], Alzheimer’s disease [15] and dementia [16]. One suggestion is that the generic attributes making 
up these measures may not be sufficiently relevant to the specific populations [17]. Longworth et al. [18] 
valued three condition-specific ‘bolt-on’ attributes as extensions to the EQ-5D  related to hearing, 
tiredness and vision, and found that the ‘bolt-on’ attributes had a significant impact on the values of the 
health states. Another reason posited for the limitation of the generic measures is that the values 
attached to the health states are generated from the general public (as recommended by NICE) rather 
than the specific population in the health states. It is argued that the general public does not have the 
same experience of the disease as patients and thus cannot reveal the true preference of the specific 
population being evaluated [19]. A further cited limitation is the discrepancies in utility values when 
measured with different preference-based instruments [20-24].  Richardson et al. [25] compared the 
utilities in patients from seven disease areas and compared them with values from healthy members 
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from the public using six instruments, including the EQ-5D, SF-6D, HUI3, 15D, Quality of Well-Being, 
and Assessment of Quality of Life (AQoL). The results revealed that the magnitude of utility difference 
varied with the choice of instrument by more than 50% for every disease group. Such evidence raises 
concerns about the external comparability of the values generated by different measures and their 
ability to reflect true QoL in patients affected by certain conditions.  
In comparison with generic QoL measures, condition-specific QoL measures are designed to be more 
sensitive in their ability to capture the impact of specific diseases or conditions on QoL of the population 
being affected. However, the QoL scores generated from such condition-specific measures are, by 
definition, restricted to the specific condition-specific profile of attributes and levels and as such cannot 
be compared meaningfully with scores obtained from other condition-specific QoL measures. 
Furthermore, those condition-specific QoL measures are typically not valued, i.e., not preference-based, 
and hence their use is restricted to ‘within-disease’ priority setting, i.e., cost-effectiveness analysis 
rather than broader priority setting frameworks such as CUA and cost-benefit analysis (CBA). The 
summary scores from condition-specific measures are typically unweighted aggregates (additive 
summation of scores to responses) rather than incorporating preference weights to responses. For 
example, in Parkinson’s, the Parkinson’s Disease Questionnaire-39-item (PDQ-39) is a common 
condition-specific non-preference-based QoL questionnaire for use in people with Parkinson’s (PwP). 
Its summary index (PDQ-39-SI) is calculated by averaging the eight attribute scores [26,27]. Despite 
accurately measuring the key condition attributes in PwP, this instrument cannot be used in CUA due 
to the lack of valuation of attributes. Without such ‘valuation’ or ‘inclusion of preferences’ for the health 
states, no information on how much society would be willing to pay for improvements in scores is 
obtained. In recent years research has begun to bridge the condition-specific measures/attributes with 
valuations, examples of which include condition-specific preference-based measures (CS-PBM) [28] 
and adding condition-specific ‘bolt-on’ attributes to EQ-5D [18]. Despite issues around comparability 
across disease areas [29], such research is an attempt to complement the limitations of current methods. 
Parkinson’s is the second most common neurodegenerative disorder in elderly people, after 
Alzheimer’s disease [30]. QoL in PwP is affected by motor and non-motor symptoms, as well as 
medication side effects [31-37]. Utility values in PwP were shown to be the lowest among 29 chronic 
conditions being evaluated [38]. To our knowledge, there are three published reviews of QoL measures 
in Parkinson’s [39-41]. Martinez-Martin et al. [39] assessed and classified the generic and specific 
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health-related QoL scales by psychometric quality to three groups, ‘recommended,’ ‘suggested,’ or 
‘listed.’ Soh et al. [40] grouped the commonly used health-related QoL measures into ’health 
utility,‘ ’health status,‘ and ’well-being’ and overviewed the use of these measures. Dodel et al. [41] 
discussed several approaches in economic evaluations in Parkinson’s including the utility instrument. 
In this study, EQ-5D, SF-6D, 15D, and HUI were assessed according to six criteria of psychometric 
properties, based on which the authors recommended the use of EQ-5D and HUI to generate utilities 
along with SG and TTO. However, these studies are not scoped exceptionally for PbQoL, and details 
were not provided for the assessment of psychometric properties due to the limited space given to 
PbQoL. Providing these details will benefit the interpretation of the recommendations considering that 
the process for assessment of psychometric properties is context-sensitive in that the choice of external 
criteria may have substantial impact on the judgement of the properties.  
The objective of this systematic review was to identify, summarize, and assess the psychometric 
properties including construct validity and responsiveness of PbQoL measures in PwP.  
 
Methods 
Search strategy 
Electronic databases were searched to identify studies which measured preferences in PwP. The 
databases included PubMed, MEDLINE, EMBASE, CINAHL, PsycINFO, Applied social sciences Index 
and Abstracts (ASSIA), Social service abstracts (CSA), AgeInfo, Database of Abstracts of Reviews of 
Effects (DARE), and NHS EED database. The initial search was conducted in November 2013 and 
updated in July 2015. A search strategy was developed together with an expert information scientist to 
maximize the chance of retrieving potential relevant studies (Appendix in ESM). 
Inclusion/exclusion criteria 
Studies were included if the utility value for people with Parkinson’s (PwP) was measured using a 
PbQoL instrument and sufficient data were provided to allow the assessment of construct validity and 
responsiveness. Studies that were eligible for the assessment of convergent validity and 
responsiveness must also contain a reference measure. The reference measure could be another 
PbQoL measure, non-preference-based QoL measure, or commonly used clinical measures in 
Parkinson’s. There are two commonly used clinical measures of Parkinson’s, Unified Parkinson's 
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Disease Rating Scale (UPDRS) and Hoehn & Yahr scale (H&Y). The UPDRS assesses clinical status 
of Parkinson’s in four domains including, mood and cognition, activities of daily living, motor symptoms 
severity, and complications of treatment [42]. The H&Y describes progression of motor function in 
Parkinson’s population, ranging from stage I (mildest) to stage V (most severe) [43]. 
For the assessment of discriminant validity, at least two groups had to be available, divided based on 
clinical characteristics related to Parkinson’s. PbQoL measure index scores had to be available for 
those groups. For the assessment of convergent validity, correlation coefficients should be reported 
between the PbQoL measure and the reference measure. For the assessment of responsiveness, at 
least two measurements or difference over a period of time (e.g., baseline and primary end point) of 
both PbQoL measure and the reference measure should be reported. Given this, studies were therefore 
excluded if the population being measured were patients without a confirmed diagnosis of Parkinson’s; 
the utilities of PwP were not measured, measured but not reported, not appropriately presented (e.g., 
EQ-5D index value not on a -0.59-1 scale), or not adequately presented for the assessment purpose; 
and a full result published later covering the shorter term result in previous papers.  
Data extraction 
After screening (YX), included studies were reviewed and the following study characteristics were 
extracted (YX): first author and publication year, country, study type, number of participants, clinical 
characteristics, and length of follow-up (when applicable). Moreover, for the purpose of assessing 
psychometric properties, study objectives, methods, the measures used, and their scores were also 
extracted. 
Assessment of construct validity and responsiveness 
Construct validity and responsiveness of the PbQoL approaches used in the included studies were 
assessed (YX) with  methods used in previous studies [18]. Construct validity represents the ability that 
an instrument measures the construct it is intended to measure [44,45]. Construct validity is typically 
assessed by examining both discriminant validity and convergent validity [18,45-49]. Discriminant 
validity is the extent to which a measure can discriminate across groups that are theoretically known to 
differ [45,50]. This method is also known as the ‘known group method’ [50]. In this review, we examined 
to what extent the utility values distinguished between patients with different clinical characteristics of 
Parkinson’s, with the premise that the QoL of the patients were expected to differ according to these 
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characteristics. Good evidence of discriminant validity deemed to be demonstrated by a statistically 
significant difference (e.g., t test). Given that statistical significance is dependent on sample size, 
appropriate differences with near significance were also considered as weaker evidence for 
discriminant validity. Convergent validation is another test of construct validity which is defined as the 
extent to which one measure correlates with another measure of the same or similar construct 
[45,46,50,51]. In this research, convergent validity is deemed to be demonstrated if the test measure is 
highly correlated (correlation coefficient (r) ≥0.5) with a measure of similar concept. A very high 
correlation (r > 0.7) is not expected in this research due to the inherent difference between the different 
types of QoL measures.  Of the studies that used two or more QoL approaches, we examined the 
correlation between the approaches; this included both PbQoL and non-preference-based QoL 
measures. In this assessment, correlations above 0.5 were considered as strong, between 0.3 and 0.5 
as moderate, and below 0.3 as weak. Responsiveness is the capacity of an instrument to accurately 
detect a change when it has occurred over a longitudinal time period [52,53]. We examined the extent 
to which PbQoL measures were able to detect changes in health states overtime as measured by 
clinical measures or Parkinson’s-specific QoL measures. The change could be due to the health 
intervention or natural progression of Parkinson’s. As with discriminant validity, good evidence of 
responsiveness is demonstrated with shown or nearly shown statistically significant difference between 
the baseline and longest follow-up time point.  
 
Results 
A total of 2758 records were retrieved after removing duplicates. Titles and abstracts were screened to 
identify relevant studies, and 2536 records were excluded based on eligibility criteria. Full text of the 
remaining 222 studies was further screened from which 23 studies were included in this review.  A 
flowchart of the screening process is shown in Fig. 1.  
Included studies were classified into two groups based on their study type for our assessment: Group 
A: cross-sectional studies [54-63] (including two case-control studies [59,63]) for assessing discriminant 
and convergent validity (n = 10, Tables 1, 2); Group B: longitudinal studies [64-76] for assessing 
responsiveness (n = 13, Table 3) . 
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Among the included studies, one study specifically targeted people with early Parkinson’s [69], three 
targeted advanced Parkinson’s [70,73,76], and the remaining studies recruited PwP with a wide range 
of severity levels. Five studies explored the relationship between QoL and specific symptoms of 
Parkinson’s, including apathy [54], depression [56,62], life stress [56], presence of dyskinesia [57], 
presence of ‘wearing off’ period of drugs [57], sweating dysfunction [63]. Among the longitudinal studies, 
there were seven RCTs [64,66,67,69,73,75,70], five prospective self-comparison study [65,68,71,74], 
and one cohort study [72]. Three studies conducted CUA [69,70,76], and one study conducted cost-
consequence analysis [75]. Two studies measured patients’ natural progression over a period [71,68]. 
Eleven studies conducted various interventions, including drugs [69,65,70,73], provision of community-
based nurse specialists [66], provision of instructions of clinical guidelines to neurologists [67], 
standardised pharmaceutical care [72], adherent therapy [64], deep brain stimulation (DBS) surgery 
[76], and multidisciplinary rehabilitation [74]. 
Among the PbQoL measures, the EQ-5D was predominantly used, reported in 20 studies [54,55,41,60-
69,71-76,57] , while the HUI-3 was reported in two studies [59,56], HUI-2 in one [62], 15D in two [55,70], 
and the Disability and distress index (DDI) (often referred to as the Rosser Index) in one [62]. The DDI, 
developed by Rosser and colleagues in 1970s, is comprised of eight levels of disability (loss of function 
and mobility) and four levels of subjective distress, describing 29 disability/distress states [77,78]. One 
single index score is available for each state, which is generated through valuation process using 
ranking and relative magnitude of severity exercise [79]. The 15D is a less commonly used instrument 
developed in Finland [80]. It was chosen in the Norwegian and Swedish studies due to its wider 
spectrum aspects of QoL, higher sensitivity with five levels on each attribute and availability of value 
sets in the specific country where the study was conducted [81,82]. Among the reference measures for 
the assessment of psychometric properties, the PDQ-39 was the most widely used Parkinson’s-specific 
QoL measure, reported in 9 studies [62-64,66,67,70,71,75,76], followed by the short version of the 
PDQ-39, the PDQ-8 in 6 studies [55,57,58,61,68,72], the Parkinson’s Disease QUAlity of LIFe scale 
(PDQUALIF) was used in one study [69], the Parkinson’s Disease Quality of Life questionnaire (PDQL) 
[71] in one, and the generic QoL instrument, the SF-36 in one [75]. The measures used in each of the 
included studies are presented in Table 4. The characteristics of the QoL measures in the included 
studies are summarized in Table 5. For transparency, we presented the evidence used for the 
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assessment of discriminant validity in Table 1, convergent validity in Table 2 and responsiveness in 
Table 3, along with the study characteristics. 
Assessment of construct validity and responsiveness 
Assessment of discriminant validity 
Four studies provided adequate evidence for the assessment of the discriminant validity of the EQ-5D-
3L [54,57,62,63], two studies for the HUI-3 [56,59], one study for the EQ-5D-5L and 15D [55], and one 
study for the DDI and HUI-II [62]. For the EQ-5D-3L, groups were defined by the presence of apathy 
('with' or 'without') [54] , the presence of dyskinesia (‘with’ or ‘without’) [57], the presence of 'wearing off' 
period (‘with’ or ‘without’) [57] and a case-control design (‘PwP with sweating disturbances’, or ‘healthy 
controls’) [63]. EQ-5D-3L index scores achieved statistically significant differences between the above-
defined groups. One remaining study by Siderowf et al. [62] assessed the ability of EQ-5D-3L, DDI and 
HUI-2 to discriminate between clinically different groups as defined by a list of criteria. It was found that 
all of the three measures could differentiate between groups with upper (severe) and lower (mild) halves 
of UPDRS score (p < 0.001) and between first (mildest) and fourth (most severe) quartiles (p < 0.001); 
however, no difference was found in the EQ-5D-3L and HUI-2 between groups with first and second 
quartiles of UPDRS scores (p = 0.88, p = 0.85 respectively) while a statistically significant difference 
was shown in the DDI (p = 0.03)  . All three measures were found to be sensitive to symptoms including 
falling, freezing, visual hallucinations and depression with a statistically significant unadjusted mean 
difference between groups divided based on these symptoms (p < 0.05). However, no difference was 
found between groups stratified by dyskinesia or fluctuations for all the three measures, and HUI-2 
failed to show difference between groups with and without swallowing difficulty (p = 0.20) [62].  
For the HUI-3, one case-control study identified a statistically significant difference between PwP and 
general population, with the HUI-3 score being 0.56 (95% CI 0.48, 0.63) and 0.87 (95% CI 0.87, 0.88) 
respectively [59]. Another study reported a statistically significant and clinically important difference in 
HUI-3 values between the groups with and without depression after adjusting for several confounders 
such as age, sex, duration of Parkinson’s etc. [56]. This study also evaluated the impact of life stress 
on HUI-3 utility values and identified statistically significant adjusted mean difference between not at 
all/not very stressful and quite a bit/extremely stressful (adjusted mean difference 0.19 (p < 0.05)), but 
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no difference found between a bit stressful and quite a bit/extremely stressful groups (0.14, p < 0.05) 
[56]. 
One study reported EQ-5D-5L and 15D values for groups with varied severity of Parkinson’s stratified 
with H&Y stages, and both instruments showed a statistically significant difference between the groups 
[55].  
Assessment of convergent validity 
Six studies presented correlation coefficients between a PbQoL measure and a reference measure for 
the assessment of convergent validity [55,62,61,60,57,58]. The EQ-5D-3L score showed strong 
correlation (r = -0.75) with the PDQ-8 summary score [57], moderate to strong correlation with H&Y 
staging (r = -0.32 [57], r = -0.53 [58]), and moderate to strong correlation with the UPDRS total score 
(absolute r ranging from 0.39 [57] to 0.72 [58,61]).  
Two studies compared multiple PbQoL measures in terms of their correlations with Parkinson’s-specific 
QoL measures, and the results were mixed [55,62]. Garcia-Gordillo et al. [55] found that the utility score 
from the 15D had a stronger correlation than the EQ-5D-5L with PDQ-8 summary score, with 
coefficients being -0.710 and -0.679, respectively. The authors explained that this could be due to the 
broad attributes of 15D such as leisure activities, housework, communication, worries about the future, 
which are likely to be substantially affected by Parkinson’s [55]. Siderowf et al. [62] compared DDI, EQ-
5D-3L, and HUI-II and found that the utility score from EQ-5D-3L correlated strongest with PDQ-39 
while DDI showed the weakest correlation. Specifically, they found that the EQ-5D-3L correlated 
strongest with ADL attribute (r = -0.69) and weakest with social support (r = -0.27), HUI-II correlated 
strongest with mobility (r = -0.62) and weakest with stigma (r = -0.12), and DDI correlated strongest with 
mobility and ADL (r = -0.42 for both) and weakest with stigma (r = 0.067) [62]. 
Assessment of responsiveness 
Thirteen studies provided adequate information to allow an assessment of responsiveness of the 
PbQoL measures, including 12 studies for the EQ-5D-3L [64-69,71-76]  and one study for the 15D [70]. 
The one 15D study, by Nyholm et al. [70] demonstrated improved QoL in the duodenal levodopa 
infusion arm compared to conventional oral polypharmacy arm on both PDQ-39 and 15D (both p < 
0.01). Six studies showed consistency between the EQ-5D-3L and the reference measures in terms of 
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the evidence for whether there was a statistically significant change overtime; the reference measures 
included UPDRS part II ADL [65], PDQ-39 [66,67,76], PDQ-8 and H&Y [68], and HAD depression [74]. 
The agreement between the EQ-5D and reference measures in the remaining six studies was 
concerned with various degrees [64,69,71-73,75]. Daley et al. [64] reported statistically significant better 
QoL as shown on PDQ-39 summary score, mobility, ADL, emotional well-being, cognition, 
communication and bodily discomfort after adherence therapy as compared to routine care in a RCT, 
but the change in EQ-5D-3L was small and not statistically significant (mean difference 0.07, 95% CI -
0.1, 0.2). Similarly, Schroder et al. [72] detected an improvement (p = 0.034) in PDQ-8 score in the 
group with standardised community pharmaceutical care for eight months and deterioration (p = 0.019) 
in the group with usual care, but the statistically significant difference was not shown in EQ-5D-3L score 
for either groups. Stocchi et al. [73] compared adjunctive ropinirole prolonged release and immediate 
release in a RCT and reported an improved UPDRS total motor score (p = 0.022), but a non-significant 
improved UPDRS ADL score (p = 0.270) and EQ-5D-3L score (p = 0.165). Reuther et al. [71] evaluated 
the change in QoL and clinical measures over one year among 145 PwP and found that clinical scores 
deteriorated (H&Y, p = 0.000, and UPDRS, p = 0.019); however the scores of PDQ-39 and PDQL 
improved (PDQ-39, p = 0.000, and PDQL, p = 0.030), and there was no difference in the EQ-5D (p = 
0.488). In contrast, two studies showed statistically significant change overtime in the EQ-5D but not in 
the reference measures [69,75]. Noyes et al. [69] compared pramipexole and levodopa in a RCT over 
four years and did not detect a difference in PDQUALIF, but EQ-5D showed a difference between the 
arms from year 2 to 3 (0.048, p = 0.03) and 3 to 4 (0.071, p = 0.04). Wade et al. [75] compared 
multidisciplinary rehabilitation program versus usual care, in which statistically significant difference was 
shown between the arms in the SF-36 physical score and EQ-5D score, while no difference found for 
PDQ-39 and SF-36 mental score. 
 
Discussion 
 
This study systematically reviewed and assessed the psychometric properties of PbQoL measures in 
PwP. The EQ-5D-3L was found to be predominantly used as the PbQoL measure in Parkinson’s while 
the PDQ-39 was the most widely used Parkinson’s-specific QoL measure among included studies. EQ-
5D-3L has achieved statistically significant difference between the known groups divided based on 
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clinical characteristics in most studies, but it may have limited sensitivity to detect differences in QoL 
among patients with mild Parkinson’s as evidenced by the subgroup analysis in the included studies 
[62]. Good evidence of discriminant validity has also been demonstrated in the HUI-3, EQ-5D-5L, 15D, 
HUI-2, and DDI despite limited evidence being available to allow the assessment. HUI-2 may be less 
sensitive among patients with mild Parkinson’s as it cannot differentiate between patients with first and 
second quartile UPDRS scores [62]. In terms of convergent validity, overall moderate to strong 
correlations were shown between the PbQoL measures (EQ-5D-3L, EQ-5D-5L, 15D, DDI, and HUI-II) 
and Parkinson’s-specific QoL measures/clinical measures. It was found that the EQ-5D-3L, DDI, and 
HUI-II all correlated strongest with the physical attributes (i.e., mobility and ADL) of PDQ-39 and 
weakest with mental and well-being attributes (i.e., social support and stigma). For responsiveness, 
most evidence was found for the EQ-5D-3L. The agreement between EQ-5D-3L and the Parkinson’s-
specific QoL/clinical measures varied across studies. Half of the studies showed that EQ-5D scores 
reflected changes in clinical status overtime as shown on the reference measures, while the other half 
failed to reach consistent conclusions between the measures.  
There is evidence from this review that the generic PbQoL measures correlate more strongly with the 
physical attributes than mental/well-being attributes of PDQ-39. Parkinson’s is a chronic, progressive 
condition which has been shown to affect mental/well-being aspects of QoL and as such it is important 
to include appropriate valuations for improvements in such attributes within priority setting decisions. 
The importance of these mental/well-being aspects is demonstrated by consistent presence of such 
attributes within Parkinson’s-specific QoL measures and by previous literature examining the effect of 
the mental and well-being aspects on PwP’s QoL [83,33]. With approximately half of the domains in 
PDQ-39/PDQ-8, PDQUALIF, and PDQL relating to aspects other than physical health, such domains, 
e.g., social communication, stigma/self-image, emotional functioning, cognition, and outlook, are highly 
likely to have a substantial impact on PwP’s QoL. A recent systematic review found that depression 
was the most frequently identified determinant of health-related QoL in PwP among all the demographic 
and clinical factors [84]. Therefore, sufficient incorporation of valuations for these broader attributes is 
crucial when measuring PbQoL in Parkinson’s. The utilities from the PbQoL measures generally 
discriminated well between groups and correlated well with Parkinson’s clinical and QoL measures. 
However, the inconsistency in findings of responsiveness between those measures cautioned that the 
change shown on clinical measures may not necessarily lead to the same change in QoL scores. 
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Reuther et al. [71] assumed that there might be other undetected factors leading to the opposite change 
of QoL scores to the clinical measures. One reason might be the fact that clinical measures such as 
H&Y and UPDRS focus mostly on the physical symptoms of Parkinson's while QoL measures are 
subjective to individuals and based on overall experience of health and well-being. This may also help 
explain our finding that the PbQoL measures that focused on physical health should be theoretically 
able to discriminate between groups defined by clinical factors. Besides this, as clinical status or 
objective health status is usually one of the primary predictors of QoL, it is reasonable to expect that 
PbQoL measures would display discriminant and convergent validity.  
Responsiveness of PbQoL measures is crucial to economic evaluations. In a bid to measure resource 
use and QALYs, economic evaluations often need to be carried out longitudinally over an appropriate 
and meaningful time horizon depending upon the intervention being assessed. Previous studies have 
suggested that the results of economic evaluations are sensitive to the change of utility values when 
chronic conditions or long-term sequelae are involved [85]; Parkinson’s is one of those conditions. 
Therefore, lack of definite evidence of responsiveness may critically undermine the results of CUA 
analysis in Parkinson’s and thus decision making as QALY gains may differ depending on the derivation 
of utility values. To overcome the limited responsiveness of generic PbQoL measures in certain 
populations, CS-PBM have been developed in recent years, e.g., in patients with asthma [86] and 
urinary incontinence [87]. Researchers were concerned that CS-PBM would lose the ability of 
comparability across disease areas, sometimes insensitive in measuring the side-effects which have 
differed symptoms from the condition, and lack of comprehensiveness in people with comorbidities due 
to the narrow scope [29,88]. However, the development of CS-PBM is argued to be valuable as it 
enriches the database of utilities measured by different approaches in a disease area where it exists 
limitations with current methods [29] and may provide valuable supplements to existing generic 
measures [88].  
There are a number of limitations of this research. Previous studies have argued that given that no gold 
standard has been established for measuring PbQoL, the test of validity can only provide a reference 
of a measure's performance rather than leading to a rigorous conclusion [89]. Our study assumed that 
the PDQ-39 or other Parkinson’s-specific measures was a ‘benchmark’ since those measures were 
designed specifically for Parkinson’s and hence they should be the most relevant measures to 
Parkinson’s. Another related limitation of the assessment methods relates to the test of convergent 
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validity. Correlating the PbQoL against another non-preference QoL measure is arguably not the best 
test of convergent validity since the former is a weighted/valued measure while the latter is not. Despite 
this, as both instruments were designed to measure QoL, the trend of the scores (i.e., higher value 
represents better QoL) should be similar and therefore the validity of the test should still provide useful 
information. The third limitation is that floor and ceiling effects were not assessed in this study. It was 
found that the EQ-5D and HUI-2 have limited ability to discriminate between patients with varied levels 
of mild Parkinson’s. This may be related to the ceiling effect of the EQ-5D and HUI-2 as found in other 
studies [90-92,24]. This ceiling effect, if present, will affect the discriminant validity and responsiveness 
of the PbQoL measure so that it cannot discriminate between people who all produce 1 (full health) but 
have different QoL in real life. Similarly, the indicator for convergent validity, the correlation coefficient 
will become lower if there are ceiling effects, because when the reference score is higher, the PbQoL 
would not change along since it is capped at 1. This effect however may not have large impact in a 
Parkinson's population in general. This is because the QoL for this population is usually at low middle 
to upper middle range as shown in the included studies, and thus it is not likely to have large proportion 
of responses of full health. A final note is that the ‘minimal clinically important difference’ (MCID) was 
not specified in the criteria for responsiveness due to the lack of information regarding how much MCID 
could be in the Parkinson’s population for the PbQoL measures. There is one published study assessing 
MCID for PDQ-39 and suggested that the MCID differs across dimensions [93]. One conference 
abstract estimated MCID for EQ-5D based on the PDQ-39 scores and the UPDRS to be 0.11 (range: 
0.08 - 0.14) and 0.10 (range: 0.04 - 0.17), respectively [94]. As no other information was found regarding 
the MCID for PbQoL in Parkinson’s, MCID was not used in our assessment criteria. Nevertheless, our 
criteria were not rigid on ‘statistically significant difference’ considering the sample size issue and thus 
‘nearly significance’ was also accepted.  
 
Conclusion 
 
The construct validity of the PbQoL measures identified in this review was generally good, but there 
were concerns regarding their responsiveness to the change in QoL overtime. Given the current 
requirement in countries such as the UK to report QALY (typically using the EQ-5D instrument) as the 
17 
 
preferred outcome measure in economic evaluations, it is therefore important to ensure adequately 
broader estimation of PwP’s utilities for resource allocation decisions in Parkinson’s. The development 
of methods to incorporate broader aspects into health care decision making may represent a valuable 
research development in this area. In addition, incorporation of the Parkinson’s-specific QoL measures 
would be beneficial alongside a generic PbQoL measure in longitudinal studies as to sensitively capture 
the full impact of QoL by Parkinson’s.  
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Database search after 
removing duplicates 
n = 2,758 
Full text screened 
n = 222 
Studies excluded (n = 199): 
Reasons: 
 Economic modelling with utility data from other sources 
(n=48) 
 Reviews, methodology, protocol (n = 48) 
 Cost study (n=16) 
 Measured QoL but did not value (n=23) 
 Updated paper existed (n=12) 
 Measured utilities but did not report (n=13) 
 Measured utilities of carers of PwP rather than PwP 
(n=5) 
 Diagnosis of Parkinson’s was not confirmed in the 
patient group (n=3) 
 Insufficient data to assess psychometric properties 
(n=31) 
Studies excluded  
(title and abstract screening)  
n = 2,536 
Included (n=23): 
 Cross-sectional studies (n=10) 
 Longitudinal studies (n = 13) 
Figure 1. Flowchart of study screening 
process 
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Table 1 
Characteristics of included studies – assessment of discriminant validity 
Study 
Publ
icati
on 
year 
Coun
try 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
Group define 
criteria(C) and 
groups (G) 
Evidence for discriminant validity: mean (standard 
deviation) Discrimina
nt validity 
assessmen
t 
Stage of 
Parkinson’s 
(Early or 
Advanced 
Other 
characteristics 
Reference measurea 
Preference-based 
measure 
Benito-
Leon  
et al. 
[54] 
2012 Spain 557 Both 
Recently 
diagnosed with 
Parkinson’s, 
duration <2 yrs, 
age ≥ 30 
Cross-
sectional 
C: presence of apathy 
defined as Lille Apathy 
Rating Scale. 
G1: Noapathetic; 
G2: Apathetic 
UPDRS motor; 
G1: 17.1 (8.5); 
G2: 24.8 (11.3); 
p < 0.001. 
H&Y; 
Higher proportion of early stages in 
G1; p < 0.001 
EQ-5D; 
G1: 0.83 (0.17); 
G2: 0.64 (0.26); p < 0.001. 
All attributes of EQ-5D showed 
sig 
 
Garcia-
Gordill
o et al. 
[55] 
2013 Spain 133 Both 
Able to answer 
questions 
independently, 
age > 18 
Cross-
sectional 
C: H&Y. 
G1: H&Y stages 1-2; 
G2: H&Y stages 3-4 
PDQ-8; 
G1: 18.30 (11.83); 
G2: 31.58 (19.56); 
p < 0.001 
EQ-5D-5L; 
G1: 0.70 (0.18); 
G2: 0.53 (0.28); 
p < 0.001. 
15D; 
G1: 0.81 (0.10); 
G2: 0.70 (0.17); 
p = 0.001 
 
Jones 
et al. 
[56] 
2009 
Canad
a 
259 Both 
Self-reported 
Parkinson’s in a 
Canadian 
Community Health 
Survey 
Cross-
sectional 
C: depression. 
G1/G2: without/with 
depression. 
C: life stress. 
G1’/G2’/G3’: not at all/ 
a bit/extremely 
stressful 
NA 
HUI-3; 
G1: 0.49 (95% CI 0.39, 0.59); 
G2: 0.20 (95% CI 0.03, 0.37); 
p (G1 vs. G2) < 0.05. 
G1’: 0.42 (95% CI 0.29, 0.55); 
G2’: 0.38 (95% CI 0.24, 0.51); 
G3’: 0.23 (95% CI 0.10, 0.36); 
p (G1’ vs. G3’) <0.05; 
p (G2’ vs. G3’) >0.05 
o 
Luo et 
al. [57] 
2009 
Singap
ore 
206 Both 
Without severe 
disabilities, 
Chinese MMSE 
score > 20 
Cross-
sectional 
C: presence of 
dyskinesia. 
G1: no dyskinesia; 
G2: with dyskinesia. 
C: presence of 
‘wearing off’ periods. 
G1’: no ‘wearing off’; 
G2’: with ‘wearing off’ 
NA 
EQ-5D; 
p (G1 vs. G2) < 0.01; 
p (G1’ vs. G2’) < 0.0001 
 
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Study 
Publ
icati
on 
year 
Coun
try 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
Group define 
criteria(C) and 
groups (G) 
Evidence for discriminant validity: mean (standard 
deviation) Discrimina
nt validity 
assessmen
t 
Stage of 
Parkinson’s 
(Early or 
Advanced 
Other 
characteristics 
Reference measurea 
Preference-based 
measure 
Pohar 
et al. 
[59] 
2009 
Canad
a 
261 Both 
- Data from 
Canadian 
Community Health 
Survey 
Cross-
sectional, 
case-control 
 
C: presence of 
Parkinson’s. 
G1: With Parkinson’s; 
G2: general population 
Age; 
G1: 68.9 (95% CI 66.6, 71.2); 
G2: 44.8 (95% CI 44.8, 44.9); 
p < 0.05. 
No. of  
medical conditions; 
G1: 3.0 (95% CI 2.5, 3.4); 
G2: 1.5 (95% CI 1.5, 1.5); 
p < 0.05 
HUI3; 
G1: 0.56 (95% CI 0.48, 0.63); 
G2: 0.87 (95% CI 0.87, 0.88); 
p < 0.05 
 
Sidero
wf et 
al. [62] 
2002 US 97 Both 
Without cognitive 
impairment 
Cross-
sectional 
C: total UPDRS score. 
G1 and G1’: upper and 
lower halves; 
G2 and G2’: 1st and 2nd 
quartiles; 
G3 and G3’: 1st and 4th 
quartiles. 
C: depression. 
G4 and G4’: with and 
without depression; 
and a various motor & 
non motor symptoms 
NA 
EQ-5D; 
Diff (G1vs.G1’):0.24; p < 0.001; 
Diff (G2vs.G2’):-0.009;p = 0.88; 
Diff (G3vs.G3’):0.40;p < 0.001; 
Diff (G4vs.G4’):0.26;p < 0.001. 
DDI; 
Diff (G1vs.G1’):0.09;p = 0.007; 
Diff (G2vs.G2’):0.01;p = 0.03; 
Diff (G3vs.G3’):0.17;p = 0.02; 
Diff (G4vs.G4’):0.17;p < 0.001. 
HUI-II; 
Diff (G1vs.G1’): 0.15;p = 0.001; 
Diff (G2vs.G2’):-0.008;p = 0.85; 
Diff (G3vs.G3’):0.25;p = 0.001; 
Diff (G4vs.G4’):0.17;p < 0.001. 
o 
Swinn 
et al. 
[63] 
2003 UK 77 Both 
Patients with 
sweating 
disturbances, 
without marked 
cognitive 
impairment or 
confusion 
Cross-
sectional, 
case-control 
Case-control. 
G1: PwP with sweating 
disturbances; 
G2: healthy controls 
PDQ-39; 
G1: 41.7 (19.5); 
G2: NA 
EQ-5D; 
G1: 0.47; 
G2: 0.85; 
p < 0.005 
 
Assessment result for discriminant validity: ‘’ evidence available to demonstrate that the PbQoL measure was able to show statistically significant difference between the known groups that were expected to differ as shown 
by the reference measure; ‘o’ some evidence available but still uncertain whether PbQoL measure can show statistically significant difference between the known groups that were expected to differ; ‘’ – evidence showing the 
PbQoL measure failed to differentiate between the known groups. 
MMSE - Mini-Mental State Examination, H&Y Hoehn & Yahr scale, HAD Hospital Anxiety and Depression Scale, SCOPA-Motor Scales for Outcomes in Parkinson’s disease – Motor examination, UPDRS Unified Parkinson's 
Disease Rating Scale, Diff mean difference between groups, sig statistically significance, C criteria, G group, NA not available. 
*Reference measure could be either another PbQoL measure, Parkinson’s-specific QoL measure, or (if the former two not available) clinical measures. 
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Table 2 
Characteristics of included studies – assessment of convergent validity 
Study 
Publ
icati
on 
year 
Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
PbQoL 
measure(
s) 
Evidence for convergent validity Converg
ent 
validity 
assessm
ent‡ 
Stage of 
Parkinson’
s (Early or 
Advanced 
Other clinical 
characteristics 
Reference 
measure a 
Correlation coefficients (r) 
Garci-
Gordillo 
et al. [55] 
2013 Spain 133 Both 
Be able to answer 
questions 
independently, 
age > 18 
Cross-sectional 
EQ-5D-5L, 
15D 
PDQ-8 
15D/PDQ-8: -0.710. 
EQ-5D-5L/PDQ-8: -0.679 
 
Luo et al. 
[57] 
2009 Singapore 31 Both 
Well enough to 
complete surveys 
Before and after 
self-comparison, 
4 yrs 
EQ-5D 
PDQ-8 SI, 
H&Y, 
UPDRS motor 
EQ-5D/PDQ-8: -0.75. 
EQ-5D/H&Y: -0.32. 
EQ-5D/UPDRS motor:-0.39 
 
Martinez-
Martin et 
al. [58] 
2014 
Argentina, 
Cuba, 
Mexico, 
US, and 
Spain 
435 Both 
Spanish native 
speakers, at any 
age and severity 
of Parkinson’s 
Cross-sectional EQ-5D 
H&Y, 
NMSS, 
MDS-UPDRS-non 
motor, 
MDS-UPDRS-motor 
EQ-5D/H&Y: -0.53. 
EQ-5D/NMSS: -0.57. 
EQ-5D/MDS-UPDRS-non motor: -0.63. 
EQ-5D/MDS-UPDRS-motor: -0.72. 
 
Rodrigue
z-
Blazquez 
et al. [60] 
2010 Spain 387 Both 
Age ≥ 30 at 
disease onset, 
with a main carer 
Cross-sectional EQ-5D SCOPA-AUT EQ-5D/SCOPA-AUT:-0.49  
Rodrigue
z-
Blazquez 
et al. [61] 
2013 
Argentina, 
Cuba, 
Mexico, 
US, and 
Spain 
435 Both 
At any age and 
severity of 
Parkinson’s 
Cross-sectional EQ-5D 
MDS UPDRS M-
EDL 
EQ-5D/UPDRS M-EDL: -0.72  
Siderowf 
et al. [62] 
2002 US 97 Both 
Without cognitive 
impairment 
Cross-sectional 
EQ-5D, 
DDI, 
HUI-II 
PDQ-39 all sub-
attributes, 
UPDRS 
EQ-5D/PDQ-39 all attributes: from -0.27 
(social support) to -0.69 (ADL). 
EQ-5D/UPDRS total: -0.61. 
HUI/ PDQ-39 all attributes: from -0.12 
(stigma) to -0.62 (mobility). 
HUI/UPDRS total: -0.59. 
DDI/PDQ-39 all attributes: from 0.067 
(stigma) to -0.42 (mobility/ADL). 
DDI/UPDRS total: -0.40 
o 
 
Assessment result for convergent validity: ‘’ evidence available to demonstrate that PbQoL measure and the reference measure were highly related (r ≥ 0.5); ‘o’ the PbQoL measure and the reference measure were 
moderately correlated (0.3 ≤ r < 0.5); ‘’ the PbQoL measure and the reference measure were weakly correlated (r < 0.3). 
NMSS Non-Motor Symptoms Scale, SCOPA-AUT SCales for Outcomes in PArkinson’s disease – AUTonomic, ADL Activities of Daily Living, H&Y Hoehn & Yahr stage, MDS UPDRS M-EDL Movement Disorders Society 
Unified Parkinson’s Disease Rating Scale – Motor Experiences of Daily Living section, r correlation coefficient 
a Reference measure could be either another PbQoL measure, Parkinson’s-specific QoL measure, or (if the former two not available) clinical measures. 
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Table 3 – Characteristics of included studies – assessment of responsiveness 
Study 
Publi
catio
n 
year 
Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
and time 
horizon 
Intervention (I) and 
comparator (C) or; 
before (B) and after 
(A) 
Evidence for responsiveness – change from baseline to 
primary endpoint: 
Mean change (standard deviation) 
Respons
iveness 
assessm
entc 
Stage of 
Parkinson’
s (Early or 
Advanced 
Other clinical 
characteristics 
Reference measurea PbQoL measure 
Daley 
et al. 
[64] 
2014 UK 76 Both 
On anti-parkinsonian 
drug(s), no dementia 
RCT, 12 wks 
I: adherence therapy; 
C: routine care 
PDQ-39; 
I : -6.8 (6.4); 
C: 2.3 (7.4); 
Diff: -9.0 (95% CI -12.2, -5.8); 
p < 0.001 
EQ-5D; 
I: 0.04 (0.3); 
C: -0.03 (0.3); 
Diff: 0.07 (95% CI -0.1, 0.2);  
p = 0.055 
 
Ebersb
ach et 
al. [65] 
2010 Germany 61 Both 
Responsive to levodopa, 
had not responded to or 
did not tolerate 
entacapone, age 30-80, 
H&Y 2-4, on stable 
medication for ≥ 4 wks 
Before and 
after self-
comparison, 
4 wks 
B and A: tolcapone 
targeting sleep quality 
UPDRS part II (ADL); 
Be: 15.1 (7.1); 
Ae: 10.8 (7.0); 
p < 0.0001 
EQ-5D; 
Be: 0.562 (0.234); 
Ae: 0.678 (0.206); 
p = 0.0001 
 
Jarma
n et al. 
[66] 
2002 UK 1859 Both 
On anti-parkinsonian 
drug(s) 
RCT, 
2 yrs 
I: provision of 
community based 
nurses specialists; 
C: no provision. 
B and A: Also analysed 
deterioration over 2 yrs’ 
of all participants 
PDQ-39; 
B and A: all sub-attributes: p <  0.05; 
Diffb: 0.47 (95% CI -2.72, 3.66); p = 
0.77 
EQ-5D; 
B and A: -0.10 (-0.12, -
0.08); p < 0.001; 
Diffb:-0.02 (95% CI -0.06, 
0.02); p = 0.30 
 
Larisch 
et al. 
[67] 
2011 Germany 386 Both Not reported 
Cluster RCT, 
9 mths 
I: providing instructions 
of clinical practice 
guidelines to 
neurologists; 
C: without instructions  
PDQ-39; 
I: 1.8 (11.2); 
C: 1.1 (11.5); 
pd=0.7591 
EQ-5D; 
I: -0.001 (0.195); 
C: 0.007 (0.209); 
pd=0.5148 
 
Luo et 
al. [68] 
2010 Singapore 31 Both 
Well enough to complete 
surveys 
Before and 
after self-
comparison, 4 
yrs 
No intervention 
PDQ-8 SI; 
Be: 17.74 (14.17); 
Ae: 35.08 (17.43); 
p < 0.0001. 
H&Y； 
Be: 2.09 (0.38); 
Ae: 2.40 (0.70); 
p = 0.0133  
EQ-5D; 
Be: 0.76 (0.23); 
Ae: 0.52 (0.33); 
p = 0.0014 
 
Noyes 
et 
al.[69]  
2006 US 301 Early 
Age  ≥  30, duration with 
Parkinson’s ≤ 7 yrs, H&Y 
1-3, required dopaminergic 
anti-Parkinson’s therapy 
RCT, 4 yrs; 
cost-utility 
analysis 
I: pramipexole; 
C: levodopa 
PDQUALIF; 
Diff over 4 yrs:0.040; 
P = 0.45. 
Diff from yr 2 ~3: 0.015; 
P = 0.36. 
EQ-5D; 
Diff over 4 yrs: 0.149; 
p=0.11. 
Diff from yr 2 ~3: 0.048; 
P = 0.03. 
o 
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Study 
Publi
catio
n 
year 
Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
and time 
horizon 
Intervention (I) and 
comparator (C) or; 
before (B) and after 
(A) 
Evidence for responsiveness – change from baseline to 
primary endpoint: 
Mean change (standard deviation) 
Respons
iveness 
assessm
entc 
Stage of 
Parkinson’
s (Early or 
Advanced 
Other clinical 
characteristics 
Reference measurea PbQoL measure 
Diff from yr 3~4: 0.036; 
P = 0.25 
Diff from yr 3~4: 0.071 
p=0.04 
Nyhol
m et 
al.[70] 
2005 Sweden 24 Advanced 
Experiencing motor 
fluctuations and dyskinesia 
Crossover 
RCT, 2 three 
wks trial plus 6 
mths follow up; 
cost-utility 
analysis 
I: duodenal levodopa 
infusion (DLI) as 
monotherapy; 
C: conventional oral 
polypharmacy 
PDQ-39; 
Ie: median 25 (range 10-42); 
Ce: median 35 (range 16-55); 
p < 0.01 
15D; 
Ie: median 0.78 (range 0.64-
0.95); 
Ce: median 0.72 (range 
0.58-0.88); 
p < 0.01 
 
Reuthe
r et al. 
[71] 
2007 Germany 145 Both Not reported 
Prospective 
self-
comparison 
non-
intervention, 
12 mths 
No intervention 
PDQ-39; 
Be: 29.4 (17.5); 
Ae: 25.6 (16.2); 
P = 0.000. 
PDQL; 
Be: 118.6 (27.5); 
Ae: 122.8 (26.1); 
P = 0.030. 
H&Y; 
Be: 2.81 (1.16); 
Ae: 3.13 (1.04); 
P = 0.000. 
UPDRS; 
Be= 48.1 (33.3); 
Ae= 53.1 (34.0); 
P = 0.019 
EQ-5D; 
Be: 0.61 (0.30); 
Ae: 0.60 (0.28); 
P = 0.488 
 
Schröd
er et 
al. [72] 
2012 Germany 161 Both 
On anti-parkinsonian 
medication(s), age > 35, 
sufficient physical and 
cognitive ability to 
complete questionnaires 
without assistance 
Cohort study, 
8 mths 
I: standardised 
community 
pharmaceutical care; 
C: usual care 
PDQ-8; 
I: -3.3 (95% CI -6.3, -0.3); 
pf=0.034. 
C: 4.4 (95% CI 0.8, 8.1); 
pf=0.019 
EQ-5D; 
I:0.02 (95% CI -0.02, 0.06); 
pf=0.29. 
C:-0.03 (95% CI -0.08,0.01); 
pf=0.13 
 
Stocch
i et al. 
[73] 
2011 
Bulgaria, 
Canada, 
Czech 
Republic, 
France, 
Hungary, 
Poland, 
Romania, 
Spain, UK. 
177 Advanced 
Age ≥30, H&Y 2-4, not 
adequately controlled on L-
dopa (3-12 hrs of daily 
awake time spent as ‘off’ 
time) 
RCT, 24 wks 
I: adjunctive ropinirole 
prolonged release; 
C: immediate release 
UPDRS total motor; 
Diff: -2.30 (95% CI -4.27, -0.33); P = 
0.022. 
UPDRS ADL in ‘off’ state; 
Diff: -0.77 (95% CI -2.13, 0.60); P = 
0.270. 
UPDRS ADL in ‘on’ state; 
Diff: -0.69 (95% CI -1.51, 0.13); 
P = 0.100 
EQ-5D; 
Diff: 0.03 (95% CI -0.01, 
0.08); 
P = 0.165 
o 
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Study 
Publi
catio
n 
year 
Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
and time 
horizon 
Intervention (I) and 
comparator (C) or; 
before (B) and after 
(A) 
Evidence for responsiveness – change from baseline to 
primary endpoint: 
Mean change (standard deviation) 
Respons
iveness 
assessm
entc 
Stage of 
Parkinson’
s (Early or 
Advanced 
Other clinical 
characteristics 
Reference measurea PbQoL measure 
Trend 
et al. 
[74] 
2002 UK 118 Both 
Score of at least 7/10 on 
Hodkinson’s mini-mental 
test, no cognitive 
impairment 
Before and 
after self-
comparison 
B and A: intensive 
multidisciplinary 
rehabilitation 
HAD anxiety: 
Be: 5.51 (3.31); 
Ae: 5.19 (3.43); 
p value not sig. 
HAD depression: 
Be: 6.06 (2.88); 
Ae: 5.57 (2.80); 
P = 0.029. 
p value of all of the other motor and 
non-motor scales achieved sig. 
EQ-5D; 
Be: 0.55 (0.24); 
Ae: 0.63 (0.22); 
P = 0.001 
 
Wade 
et al. 
[75] 
2003 UK 94 Both 
Without severe cognitive 
losses 
Crossover 
RCT, 24 wks; 
vost-
consequence 
analysis 
I: multidisciplinary 
rehabilitation program; 
C:usual care 
PDQ-39; 
B: 25.5 (10.7); 
A: 26.0 (12.7); 
P = 0.687. 
SF-36 physical; 
B: 29.5 (11.1); 
A: 27.28 (10.9); 
P = 0.046. 
SF-36 mental; 
B: 51.0 (8.4); 
A: 50.5 (10.3); 
P = 0.655  
EQ-5D; 
B: 0.72 (0.22); 
A: 0.66 (0.21); 
P = 0.026 
o 
Zhu et 
al. [76] 
2014 HK (China) 13 Advanced 
Disabling or troubling 
motor symptoms, dopa 
responsive, clear 
understanding risk of and 
realistic about surgery 
outcomes, age<70 
Prospective 
before and 
after self-
comparison, 2 
yrs; 
cost utility 
analysis 
(before-after) 
B and A: deep brain 
stimulation surgery 
PDQ-39; 
Be=39 (13); 
Ae=27 (14); 
P = 0.019. 
EQ-5D; 
Be=0.504(0.24); 
Ae=0.662(0.13); 
P = 0.033. 
 
ADL activities of daily living, H&Y Hoehn & Yahr scale, HAD Hospital Anxiety and Depression scale, UPDRS Unified Parkinson's Disease Rating Scale, I intervention group, C control group, B before, A after, Diff difference of 
scores between the changes of the two comparative groups over the trial period, yrs years, mths months, hrs hours, sig significant 
a Reference measure could be either another PbQoL measure, Parkinson’s-specific QoL measure, or (if the former two not available) clinical measures. 
b Difference between the intervention group and the control group at endpoint (no difference was found between two groups at baseline.) 
c Assessment result for responsiveness: ‘’ evidence available to demonstrate that PbQoL measure and the reference measure were consistent; ‘o’ weak evidence available but uncertain; or the PbQoL measure and the 
reference measure were not always consistent; ‘’ the PbQoL measure and the reference measure were inconsistent. 
d Hypothesis testing if the difference in change overtime between the intervention and the control group equals to zero 
e Score at either baseline or endpoint, instead of change overtime 
f Hypothesis testing if the change within group overtime equals to zero
29 
 
Table 4. Measures used in the included studies 
Study 
PbQoL instruments  Non-preference based QoL instruments   
Commonly used 
clinical measures of 
Parkinson’s 
EQ-5D 
EQ-
VAS 
HUI-3 HUI-2 15D DDI  PDQ-39 PDQ-8 
PDQU
ALIF 
SF-36 PDQL  UPDRS H&Y 
Studies for assessment of discriminant and convergent validity (n=10)            
Benito-Leon et al. 2012 [54]                
Garcia-Gordillo et al. 2013 [55] b               
Jones et al. 2009 [56]                
Luo et al. 2009 [57]                
Martinez-Martin et al. 2014 [58]              a  
Pohar et al. 2009 [59]                
Rodriguez-Blazquez et al. 2010 [60]                
Rodriguez-Blazquez et al. 2013 [61]              a  
Siderowf et al. 2002 [62]                
Swinn et al. 2003 [63]                
Studies for assessment of responsiveness (n=13)            
Daley et al. 2014 [64]                
Ebersbach et al. 2010 [65]                
Jarman et al. 2002 [66]                
Larisch et al. 2011[67]                
Luo et al. 2010 [68]                
Noyes et al. 2006 [69]                
Nyholm et al. 2005 [70]                
Reuther et al. 2007 [71]                
Schröder et al. 2012 [72]                
Stocchi et al. 2011 [73]                
Trend et al. [74]                
Wade et al. 2003 [75]                
Zhu et al. 2014 [76]                
EQ-5D Euroqol EQ-5D-3L, EQ-VAS EuroQol Visual Analogue Scale, HUI-3 Health Utilities Index – Mark 3, HUI-2 Health Utilities Index – Mark 2,  15D 15 Dimensions, DDI Disability and Distress Index, PDQ-39 Parkinson’s 
Disease Questionnaire-39-item, PDQ-8 Parkinson’s Disease Questionnaire-8-item, PDQUALIF Parkinson’s Disease QUAlity of LIFe scale, SF-36 Short-Form 36-item, PDQL Parkinson’s Disease Quality of Life questionnaire, 
H&Y Hoehn and Yahr scale, UPDRS Unified Parkinson's Disease Rating Scale 
a Movement disorder society - UPDRS 
b EQ-5D-5L
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Table 5 Characteristics of the health-related QoL instruments in the included studies  
Name 
Generic or 
Parkinson’s 
specific 
Possible score range Dimensions (D) / attributes 
PbQoL measures  
EuroQoL EQ-5D [6] Generic -0.594 (worst) ~ 1 (full health) 
5D: mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression 
HUI-2 
(Health Utilities Index 
– Mark 2) [9] 
Generic -0.03 (worst) ~ 1 (full health) 
6D: sensation, mobility, emotion, cognition, self-care, 
and pain 
HUI-3 
(Health Utilities index 
– Mark 3) [10] 
Generic 
-0.36 (worst) ~ 1 (full health) 
8D: vision, hearing, speech, ambulation, dexterity, 
emotion, cognition, and pain 
15D (15 Dimensions) 
[80] 
Generic 0 (being dead) ~ 1 (full health) 
15D: mobility, vision, hearing, breathing, sleeping, 
eating, speech, elimination (bladder and bowel 
function), usual activities, mental function, discomfort 
and symptoms, depression, distress, vitality, and sexual 
activity. 
DDI (Disability and 
distress index, or 
Rosser Index) [78] 
Generic −1.486 (worst) ~ 1.0 (full health) 2D: disability and distress 
Non-preference based QoL measures 
SF-36 (Short-Form 
36-item) [95] 
Generic 
Physical summary: 0 (worst) ~ 400 
(full health) 
Mental summary: 0 (worst) ~ 400 (full 
health) 
8D: physical functioning, role physical, bodily pain, 
general health perceptions, vitality, role emotional, 
social role functioning, and mental health 
PDQ-39/8 
(Parkinson’s Disease 
Questionnaire -39/8-
item) [27] 
Specific 0 (best) -100 (worst) 
8D: mobility, activities of daily living, emotions, stigma, 
social support, cognition, communication, and bodily 
discomfort 
PDQUALIF 
(Parkinson’s Disease 
QUAlity of LIFe 
scale) [96] 
Specific 0 (best) -100 (worst) 
7D: social/ role function, self-image/ sexuality/sleep, 
outlook, physical function, independence, urinary 
function and one global health-related quality of life item 
PDQL  
(Parkinson’s Disease 
Quality of Life 
questionnaire) [97] 
Specific 37 (worst) -185 (best) 
4D: Parkinsonian symptoms, systemic symptoms, 
emotional functioning, and social functioning 
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Appendix I 
Search strategy and No. of results in each database  
Search first run: 26 November, 2013 
Search update: 9 June 2015 (same search strategy, only limit the date, 01/01/2013- present 
(9 June 2015)) 
 
PUBMED 
1st Result: 1196 
2nd Result: 314 
Search (((parkinsonian disorders[MeSH Terms]) OR parkinson*[Title/Abstract])) AND 
((((((((((((((((((((((((((((((((((((((((cost effective*[Title/Abstract]) OR Cost-Benefit 
Analysis[Mesh]) OR Quality of Well-being[Title/Abstract]) OR Quality of 
Wellbeing[Title/Abstract]) OR QWB[Title/Abstract]) OR Health Utilities Index[Title/Abstract]) 
OR cost benefit*[Title/Abstract]) OR visual analogue scale[Title/Abstract]) OR time trade off) 
OR time tradeoff) OR standard gamble) OR discrete choice) OR dce) OR conjoint analysis) 
OR contingent valuation) OR preference*[Title/Abstract]) OR utility[Title/Abstract]) OR 
willingness to pay[Title/Abstract]) OR wtp[Title/Abstract]) OR QALY[Title/Abstract]) OR 
Quality-Adjusted Life Years[MeSH Terms]) OR QALE[Title/Abstract]) OR 
QALD[Title/Abstract]) OR Qtime[Title/Abstract]) OR quality adjusted life 
expectancy[Title/Abstract]) OR DALY[Title/Abstract]) OR Disability adjusted 
life[Title/Abstract]) OR HYE[Title/Abstract]) OR HYEs[Title/Abstract]) OR healthy year 
equivalent) OR SF-6D[Title/Abstract]) OR SF6D[Title/Abstract]) OR EuroQOL[Title/Abstract]) 
OR Euro qol[Title/Abstract]) OR EQ-5D[Title/Abstract]) OR HUI[Title/Abstract]) OR 
EQ5D[Title/Abstract]) OR HUI1[Title/Abstract]) OR HUI2[Title/Abstract]) OR 
HUI3[Title/Abstract]) Filters: English 
 
 
Ovid MEDLINE® In-Process & Other Non-Indexed Citations and Ovid MEDLINE® 
 1946 to Present with Daily & Weekly Update 
1st Result: 1202 
2nd Result: 300 (01/01/2013-current) 
Search Strategy: 
1     exp "cost effective"/  
2     cost effective*.ab.  
3     cost utility*.ab.  
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4     cost benefit*.ab.  
5     cost benefit analysis.sh.  
6      visual analogue scale.ab.  
7      standard gamble.af.  
8      time trade off.af.  
9      time tradeoff.mp  
10     dce.mp.  
11     discrete choice.mp.  
12     conjoint analysis.af.  
13     willingness to pay.mp.  
14     wtp.mp. 
15     Patient Preference/ or preference.mp.  
16     preference*.ab. 
17     contingent valuation.mp. 
18     QALY$.mp. or Quality-Adjusted Life Years/  
19     QALE$.mp.  
20     QALD$.mp.  
21     Qtime$.mp.  
22     quality adjusted life expectancy.mp.  
23     quality adjusted life day$.mp. 
24     DALY$.mp. 
25     Disability adjusted life.mp. 
26     HYE.mp. 
27     HYEs.mp.  
28     Health$ year$ equivalent$.mp. 
29     SF-6D.mp.  
30     SF6D.mp.  
31     EuroQOL.mp. 
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32     Euro qol.mp.  
33     EQ-5D.mp.  
34     EQ5D.mp. 
35     HUI.mp. 
36     HUI1.mp. 
37     HUI2.mp. 
38     HUI3.mp. 
39     Health Utilities Index.mp.  
40     QWB.mp. 
41     Quality of Wellbeing.mp.  
42     Quality of Well-being.mp.  
43     utilit$.mutilitp.  
44     or/1-43  
45     parkinson*.ab.  
46     parkinsonian disorders.sh.  
47     45 or 46  
48     44 and 47  
49     limit 48 to english language  
 
 
Embase 
1947 – Present, updated daily 
1st Result: 1516 
2nd Result: 553 (01/01/2013-current) 
 
1. Parkinsonian Disorders/  
2. parkinson*.ab.  
3. Parkinsonian Disorders.sh. 
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4. 1 or 2 or 3  
5. cost effective*.ab.  
6. cost utility*.ab.  
7. cost benefit*.ab.  
8. cost benefit analysis.sh.  
9. visual analogue scale.ab.  
10. time trade off.af.  
11. standard gamble.af.  
12. Patient Preference/ or preference.mp.  
13. preference*.ab.  
14. discrete choice.mp.  
15. conjoint analysis.af.  
16. utilit$.mp.  
17. willingness to pay.mp.  
18. wtp.mp.  
19. dce.mp.  
20. contingent valuation.mp.  
21. QALY$.mp. or Quality-Adjusted Life Years/  
22. QALE$.mp.  
23. QALD$.mp.  
24. Qtime$.mp.  
25. quality adjusted life expectancy.mp.  
26. quality adjusted life day$.mp.  
27. DALY$.mp.  
28. Disability adjusted life.mp.  
29. HYE.mp.  
30. HYEs.mp.  
31. Health$ year$ equivalent$.mp.  
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32. SF-6D.mp. 
33. SF6D.mp.  
34. EuroQOL.mp.  
35. Euro qol.mp.  
36. EQ-5D.mp.  
37. EQ5D.mp.  
38. HUI.mp.  
39. HUI1.mp.  
40. HUI2.mp.  
41. HUI3.mp.  
42. Health Utilities Index.mp.  
43. QWB.mp.  
44. Quality of Wellbeing.mp.  
45. Quality of Well-being.mp.  
46. time tradeoff.mp.  
47. exp "cost benefit analysis"/ or exp "cost effectiveness analysis"/  
48. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 
or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47  
49. 4 and 48  
50. limit 49 to (human and english language)  
 
 
CINAHL (EBSCO) 
1st Result: 102 
2nd Result: 25 (01/01/2013-present) 
 
S1 MW parkinsonian disorders 
S2 AB parkinson* 
S3 S1 OR S2 
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S4 MW quality adjusted life years 
S5 AB cost effective* 
S6 AB cost utility 
S7 MW cost benefit analysis 
S8 AB cost benefit 
S9 TX visual analogue scale 
S10 TX time trade off 
S11 TX standard gamble 
S12 AB preference* 
S13 TX discrete choice 
S14 TX conjoint analysis 
S15 TX willingness to pay 
S16 TX time tradeoff 
S17 TX dce 
S18 AB utilit* 
S19 TX wtp 
S20 TX contingent valuation 
S21 (MH "Quality-Adjusted Life Years") OR "QALY" 
S22 TX hye 
S23 TX hyes 
S24 TX qaly 
S25 TX qale 
S26 TX Quality adjusted life expectancy 
S27 TX QALD 
S28 TX quality adjusted life days 
S29 TX DALY 
S30 TX disability adjusted life 
S31 TX health* year* equivalent 
S32 TX eq5d 
S33 TX hui1 
S34 TX hui2 
S35 TX hui3 
S36 TX eq-5d 
S37 TX euroqol 
S38 TX euro qol 
S39 TX sf 6d 
S40 TX sf6d 
S41 TX health utilit* index 
S42 TX qwb 
S43 TX quality of wellbeing 
S44 TX quality of well being 
S45 
S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR 
S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR 
S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR 
S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR 
S41 OR S42 OR S43 OR S44 
S46 S3 AND S45 
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S47 S3 AND S45 (Limiters - English Language ) 
  
 
 
PsycINFO(EBSCO) 
1st Result: 440 
2nd Result: 213 (01/01/2013-present) 
S1 MM "Parkinsonism" 
S2 AB parkinson* 
S3 S1 AND S2 
S4 MM "Quality of Life" OR MM "Quality of Work Life" 
S5 AB cost effective* 
S6 AB cost utility 
S7 TX visual analogue scale 
S8 TX time trade off 
S9 TX standard gamble 
S10 AB preference* 
S11 TX discrete choice 
S12 TX conjoint analysis 
S13 TX willingness to pay 
S14 TX time tradeoff 
S15 TX dce 
S16 TX wtp 
S17 TX contingent valuation 
S18 QALY 
S19 TX qaly 
S20 TX disability adjusted life 
S21 TX quality adjusted life year* 
S22 TX eq5d 
S23 TX EQ-5D 
S24 TX hui1 
S25 TX hui2 
S26 TX hui3 
S27 TX euroqol 
S28 TX utilit* 
S29 TX sf 6d 
S30 TX sf6d 
S31 
S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR 
S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR 
S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR 
S29 OR S30 
S32 S1 OR S2 
S33 S31 AND S32 
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Applied Social Sciences Index and Abstracts (ASSIA) (Proquest) 
1st Result: 30 
2nd Result: 6 (01/01/2013-present) 
 
 (ab(parkinson*) OR su(parkinsonian disorders))  AND (su(cost effective*) OR ab(cost 
effective*) OR ab(cost utility) OR ab(cost benefit) OR su(cost - benefit analysis) OR 
(standard gamble) OR (time trade off) OR (visual analogue scale) OR (discrete choice) OR 
ab(preference*) OR (conjoint analysis) OR (willingness to pay) OR (contingent valuation) OR 
(time tradeoff) OR (dce) OR (wtp) OR su(Quality-Adjusted Life Years) OR (QALY) OR 
(QALE) OR (QALD) OR (Qtime) OR (quality adjusted life expectancy) OR (quality adjusted 
life day*) OR (DALY) OR (disability adjusted life) OR (hye) OR (hyes) OR (health* year* 
equivalent*) OR (sf6d) OR (sf 6d) OR (euroqol) OR (euro qol) OR (eq 5d) OR (eq5d) OR 
(hui) OR (hui1)  OR (hui2) OR (hui3) OR (health utilities index) OR (qwb) OR (quality of 
wellbeing) OR (quality of well being) OR ab(utility*)) 
 
 
SOCIAL service abstract (SSA) (Proquest) 
1st Result: 2 
2nd Result: 1 (01/01/2013-present) 
(ab(parkinson*) OR su(parkinsonian disorders))  AND (su(cost effective*) OR ab(cost 
effective*) OR ab(cost utility) OR ab(cost benefit) OR su(cost - benefit analysis) OR 
(standard gamble) OR (time trade off) OR (visual analogue scale) OR (discrete choice) OR 
ab(preference*) OR (conjoint analysis) OR (willingness to pay) OR (contingent valuation) OR 
(time tradeoff) OR (dce) OR (wtp) OR su(Quality-Adjusted Life Years) OR (QALY) OR 
(QALE) OR (QALD) OR (Qtime) OR (quality adjusted life expectancy) OR (quality adjusted 
life day*) OR (DALY) OR (disability adjusted life) OR (hye) OR (hyes) OR (health* year* 
equivalent*) OR (sf6d) OR (sf 6d) OR (euroqol) OR (euro qol) OR (eq 5d) OR (eq5d) OR 
(hui) OR (hui1)  OR (hui2) OR (hui3) OR (health utilities index) OR (qwb) OR (quality of 
wellbeing) OR (quality of well being) OR ab(utility*)) 
 
 
AgeInfo open search 
1st Result: 15 
2nd Result: 1 (01/01/2013-present) 
Parkinson* and quality of life 
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Database of Abstracts of Reviews of Effects (DARE) (CRD York) 
1st Result: 51 
2nd Result: 8 (01/01/2013-present) 
(Parkinson*) AND (quality of life) OR (utility*) IN DARE 
 
 
NHS Economic evaluation database (NHS EED) 
1st Result: 26 
2nd Result: 2 (01/01/2013-present) 
(Parkinson*) AND (quality of life) OR (utility*) IN NHSEED 
 
 
